Drug Trial Radar · NCT07129382
A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
220
Planned (sponsor's estimate)
Start
Sep 8, 2025
Primary completion
Sep 18, 2027
Study completion Sep 18, 2027
Sponsor
- Lead sponsor
- Chipscreen Biosciences, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
" This study consists of two parts: Part 1 (Dose Escalation): A randomized, double-blind, placebo-controlled phase in which approximately 20 to 30 adult patients with plaque psoriasis will receive the investigational treatment for 4 weeks. Part 2 (Efficacy and Safety Assessment): A randomized, double-blind, placebo-controlled evaluation where approximately 200 adult patients with plaque psoriasis will undergo 12 weeks of treatment. The resulting data will provide preliminary evidence on the safety and efficacy profile of CS32582, informing its subsequent development strategy.
Conditions
- Plaque Psoriasis
Interventions
CS32582 capsule(low dose) or matched placeboDrug
CS32582 capsule(low dose) or matched placebo,4 weeks
CS32582 capsule(high dose) or matched placeboDrug
CS32582 capsule(high dose) or matched placebo,4 weeks
CS32582 capsule(low dose)Drug
CS32582 capsule(low dose),12 weeks
CS32582 capsule(medium dose)Drug
CS32582 capsule(medium dose),12 weeks
CS32582 capsule(high dose)Drug
CS32582 capsule(high dose),12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1:Incidence and Severity of Adverse Events (AEs)Time frame: 5 weeks
- Part 2:Proportion of patients achieved Psoriasis Area Severity Index (PASI) 75 at Week 12Time frame: Week 12
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Not yet recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Affiliated Hospital of Chengde Medical University
Chengde, Hebei, China · Not yet recruiting
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Recruiting
Shiyan People's Hospital
Shiyan, Hubei, China · Not yet recruiting
Shandong Provincial Hospital for Skin Diseases
Jinan, Shandong, China · Not yet recruiting
First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China · Not yet recruiting
The Second Affiliated Hospital of Xi'an Jiaotong University(Xibei Hospital )
Xi’an, Shanxi, China · Not yet recruiting
Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
Hangzhou, Zhejiang, China · Not yet recruiting
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Yiwu, Zhejiang, China · Not yet recruiting
The First Affliated Hospital of Wenzhou Medical University
Wenzhou, Zhengjiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.